ProKidney Corp. (PROK) - Latest Market Data

Price & Market Data

Price: $1.75

Daily Change: $0.00 / 0.00%

Daily Range: $1.73 - $1.81

Market Cap: $528,604,320

Daily Volume: 457,942

Performance Metrics

1 Week: 2.62%

1 Month: -17.14%

3 Months: -19.41%

6 Months: -15.14%

1 Year: 135.3%

YTD: -22.93%

About ProKidney Corp. (PROK)

Access a quick overview of ProKidney Corp. (PROK). Trading at 1.75, the stock recorded a daily change of $0.00 / 0.00%. Its market cap is 528,604,320. Discover its performance over 3 months (-19.41%) and 6 months (-15.14%).

Company Details

Employees: 231

Sector: Health technology

Industry: Biotechnology

Country: United States

Details

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Selected stocks

Sequans Communications S.A. (SQNS)

SunPower Inc. (SPWR)

BioLineRx Ltd. (BLRX)

17 Education & Technology Group Inc. (YQ)